XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 15 2008 - 7:35AM
PR Newswire (US)
VALLEY COTTAGE, N.Y., May 15 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announced today
that Ron Bentsur, the Company's Chief Executive Officer, is
scheduled to present at the Rodman & Renshaw 5th Annual Global
Healthcare Conference. Mr. Bentsur will present an overview of the
Company including a discussion of Bicifadine, the Company's
late-stage clinical compound for the treatment of diabetic
neuropathic pain. Mr. Bentsur's presentation will take place on
Tuesday, May 20, 2008, at 11:40 am local time in Monte Carlo (5:40
am Eastern Daylight Time), at the Le Meridien Beach Plaza Hotel in
Monte Carlo, Monaco. A live webcast of the presentation will be
available at: http://www.wsw.com/webcast/rrshq13/xtlb. An archived
version of the webcast will be available following the conclusion
of the live presentation. ABOUT XTL BIOPHARMACEUTICALS LTD. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of diabetic neuropathic pain and
HCV. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of diabetic neuropathic pain,
which is currently in a Phase 2b study. XTL has out-licensed its
novel pre-clinical HCV small molecule inhibitor program. XTL also
has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly
traded on the NASDAQ and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd.
CONTACT: Ron Bentsur, Chief Executive Officer, XTL
Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024